Viatris to buy Pacira for $1.65 billion
Compartilhar
Pacira BioSciences (NASDAQ:PCRX) agreed to be acquired by Viatris (NASDAQ:VTRS) for $36.50 per share in cash through a tender offer, valuing Pacira’s equity at approximately $1.65 billion.
Pacira BioSciences (NASDAQ:PCRX) agreed to be acquired by Viatris (NASDAQ:VTRS) for $36.50 per share in cash through a tender offer, valuing Pacira’s equity at approximately $1.65 billion.
Viatris (NASDAQ:VTRS) has officially commenced the global expansion of its cardiovascular portfolio with the launch of Inpefa (sotagliflozin) in the United Arab Emirates, marking the first commercial availability of the therapy outside the United States.
Viatris (NASDAQ:VTRS) received approval from Japan’s Ministry of Health, Labour and Welfare for WAKIX (pitolisant) to treat excessive daytime sleepiness associated with obstructive sleep apnea syndrome and narcolepsy.
Harrow (NASDAQ:HROW) closed the acquisition of TYRVAYA from Viatris to expand its commercial ophthalmic portfolio with an approved dry eye treatment.
Viatris (NASDAQ:VTRS) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Effexor® SR (venlafaxine hydrochloride) sustained-release capsules for the treatment of adults with generalized anxiety disorder (GAD).
